Movatterモバイル変換


[0]ホーム

URL:


DK2714738T3 - Multivalente og monovalente multispecifikke komplekser og deres anvendelser - Google Patents

Multivalente og monovalente multispecifikke komplekser og deres anvendelser
Download PDF

Info

Publication number
DK2714738T3
DK2714738T3DK12726532.0TDK12726532TDK2714738T3DK 2714738 T3DK2714738 T3DK 2714738T3DK 12726532 TDK12726532 TDK 12726532TDK 2714738 T3DK2714738 T3DK 2714738T3
Authority
DK
Denmark
Prior art keywords
antibody
mrd
target
bind
binding
Prior art date
Application number
DK12726532.0T
Other languages
English (en)
Inventor
Viktor Roschke
David Lafleur
David M Hilbert
Peter Kiener
Original Assignee
Zyngenia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zyngenia IncfiledCriticalZyngenia Inc
Application grantedgrantedCritical
Publication of DK2714738T3publicationCriticalpatent/DK2714738T3/da

Links

Classifications

Landscapes

Claims (11)

1. Modulært genkendelsesområde (Modular Recognition Domain MRD), hvor MRD er en peptid i stand til binding af ANG2, og hvor MRD omfatter sekvensen SEQ ID NO: 16. SEQ ID No 16: DCAVYPNPPWCYKMEFGK.
2. Kompleks omfattende MRD ifølge krav 1 funktionsmæssigt linket til et antistof.
3. Kompleks ifølge krav 2, hvor antistoffet binder til VEGF (eksempelvis VEGFA eller VEGFB), FGF1, FGF2, FGF4, FGF7, FGF8b, FGF19, FGFR1 (eksempelvis FGFR1-IIIC), FGFR2 (eksempelvis FGFR2-IIIa, FGFR2-IIIb, og FGFR2-IIIc), FGFR3, TNF, EFNal, EFNa2, ANG1, ANG2, IE1, IElbeta, IL6, IL8, IE18, HGF, PDGFA, PLGF, PDGFB, CXCL12, KIT, GCSF, CXCR4, PTPRC, TIE2, VEGFR1, VEGFR2, VEGFR3, Notch 1, DLL4, EGFL7, a2pi-integrin, a4pi-integrin, α5β1-integrin, av33-integrin, TGFb, MMP2, MMP7, MMP9, MMP12, PLAU, VCAM1, PDGFRA eller PDGFRB.
4. Kompleks ifølge krav 2, hvor antistoffet binder til TNF.
5. Kompleks ifølge krav 2, hvor antistoffet er adalimumab.
6. Kompleks ifølge krav 2, hvor antistoffet kæmper med adalimumab om binding til TNF.
7. Pharmaceutisk sammensætning ifølge et hvilket som helst af kravene 2-6.
8. Kompleks ifølge et hvilket som helst af kravene 2 - 6 til anvendelse ved en fremgangsmåde til behandling af en autoimmun lidelse.
9. Kompleks ifølge et hvilket som helst af kravene 2 - 6 til anvendelse ved en fremgangsmåde til behandling af reumatisk arthritis, Crohns sygdom, systemisk lupus erythematosus, inflammatorisk tarmsygdom, psoriasis, diabetes, ulcerativ colitis eller multipel sclerose.
10. Kompleks ifølge et hvilket som helst af kravene 4 - 6 til anvendelse ved en fremgangsmåde til behandling af arthritis.
11. Kompleks ifølge et hvilket som helst af kravene 8-10, hvor komplekset er til anvendelse med en proteinkinase-inhibitor.
DK12726532.0T2011-05-242012-05-24Multivalente og monovalente multispecifikke komplekser og deres anvendelserDK2714738T3 (da)

Applications Claiming Priority (4)

Application NumberPriority DateFiling DateTitle
US201161489249P2011-05-242011-05-24
US201261597714P2012-02-102012-02-10
US201261610831P2012-03-142012-03-14
PCT/US2012/039469WO2012162561A2 (en)2011-05-242012-05-24Multivalent and monovalent multispecific complexes and their uses

Publications (1)

Publication NumberPublication Date
DK2714738T3true DK2714738T3 (da)2019-01-28

Family

ID=46229931

Family Applications (1)

Application NumberTitlePriority DateFiling Date
DK12726532.0TDK2714738T3 (da)2011-05-242012-05-24Multivalente og monovalente multispecifikke komplekser og deres anvendelser

Country Status (8)

CountryLink
US (3)US20140065142A1 (da)
EP (1)EP2714738B1 (da)
CN (2)CN106432506A (da)
AU (2)AU2012258637B2 (da)
CA (1)CA2837169C (da)
DK (1)DK2714738T3 (da)
ES (1)ES2704038T3 (da)
WO (1)WO2012162561A2 (da)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
AU2008346734A1 (en)2008-01-032009-07-16The Scripps Research InstituteAntibody targeting through a modular recognition domain
US20120100166A1 (en)2010-07-152012-04-26Zyngenia, Inc.Ang-2 Binding Complexes and Uses Thereof
US9623117B2 (en)*2011-04-042017-04-18Wisconsin Alumni Research FoundationMethod for selective targeting and entry of bacterial toxins to cells
ES2704038T3 (es)2011-05-242019-03-13Zyngenia IncComplejos multiespecíficos multivalentes y monovalentes y sus usos
US10398696B2 (en)2013-03-122019-09-03Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek ZiekenhuisCombinations for treatment of cancer
PH12022550138A1 (en)2013-03-132023-03-06Amgen IncProteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en)2013-03-132016-10-04Amgen Inc.Proteins specific for BAFF and B7RP1
CN105451767B (zh)*2013-03-152019-10-18泽恩格尼亚股份有限公司多价和单价多特异性复合物及其用途
KR102049990B1 (ko)2013-03-282019-12-03삼성전자주식회사c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
LT3027651T (lt)2013-08-012019-04-10Five Prime Therapeutics, Inc.Afukozilinti anti-fgfr2iiib antikūnai
EP3842528A1 (en)2013-09-182021-06-30Kymab LimitedMethods, cells and organisms
EP3757130A1 (en)2013-09-262020-12-30Costim Pharmaceuticals Inc.Methods for treating hematologic cancers
JP6174811B2 (ja)2013-12-112017-08-02リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc.ゲノムの標的改変のための方法及び組成物
WO2015095972A1 (en)2013-12-232015-07-02The Centre For Drug Research And DevelopmentAntibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof
JOP20200094A1 (ar)2014-01-242017-06-16Dana Farber Cancer Inst Incجزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)2014-01-312017-06-16Children’S Medical Center Corpجزيئات جسم مضاد لـ tim-3 واستخداماتها
DK3099713T3 (da)2014-02-022020-04-14Medimmune LtdKimært protein bestående af et ngf-antagonistdomæne og et tnfa-antagonistdomæne
HUE057205T2 (hu)2014-02-042022-04-28PfizerPD-1 antagonista és VEGFR inhibitor kombinációja rák kezelésére
EA201691765A1 (ru)2014-03-142016-12-30Новартис АгМолекулы антител против lag-3 и их применения
EP3129052B1 (en)*2014-04-082020-06-03Seattle Genetics, Inc.Optimal dosing of a cd19-antibody drug conjugate
SMT202100116T1 (it)2014-05-282021-05-07Agenus IncAnticorpi anti-gitr e metodi di utilizzo degli stessi
ES2890079T3 (es)2014-05-292022-01-17Macrogenics IncMoléculas de unión triespecíficas y métodos de uso de las mismas
GB201409558D0 (en)2014-05-292014-07-16Ucb Biopharma SprlMethod
US9840553B2 (en)2014-06-282017-12-12Kodiak Sciences Inc.Dual PDGF/VEGF antagonists
WO2016001810A1 (en)*2014-07-012016-01-07Pfizer Inc.Bispecific heterodimeric diabodies and uses thereof
GB201412658D0 (en)*2014-07-162014-08-27Ucb Biopharma SprlMolecules
GB201412659D0 (en)2014-07-162014-08-27Ucb Biopharma SprlMolecules
RU2718914C2 (ru)2014-09-132020-04-15Новартис АгСочетанные способы лечения с использованием ингибиторов alk
CN107208076A (zh)2014-10-172017-09-26科达制药丁酰胆碱酯酶两性离子聚合物缀合物
CA2970924A1 (en)*2014-10-312016-05-06H. Lee Moffitt Cancer Center And Research Institute, Inc.Tetravalent tlr9 bispecific antibody
EP3233917B1 (en)*2014-12-192024-04-17Chiome Bioscience, IncFusion protein comprising three binding domains to 5t4 and cd3
WO2016115171A1 (en)*2015-01-162016-07-21The Regents Of The University Of CaliforniaInsulin-like growth factor 2 (igf2) signaling and modulation
CN104774268B (zh)*2015-01-212018-09-28武汉友芝友生物制药有限公司一种双特异性抗体egfr×cd3的构建及应用
EP3262073A1 (en)2015-02-262018-01-03Merck Patent GmbHPd-1 / pd-l1 inhibitors for the treatment of cancer
WO2016145385A2 (en)*2015-03-112016-09-15Integrated Biotherapeutics, Inc.Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails
US10196445B1 (en)*2015-03-172019-02-05Bristol-Myers Squibb CompanyIpilimumab variant with enhanced ADCC
AU2016280003B2 (en)2015-06-162021-09-16Merck Patent GmbhPD-L1 antagonist combination treatments
GB201601077D0 (en)2016-01-202016-03-02Ucb Biopharma SprlAntibody molecule
GB201601073D0 (en)2016-01-202016-03-02Ucb Biopharma SprlAntibodies
GB201601075D0 (en)*2016-01-202016-03-02Ucb Biopharma SprlAntibodies molecules
JP6933379B2 (ja)*2015-09-242021-09-08ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル転移を低減するための方法および組成物
SMT202300017T1 (it)*2015-10-022023-03-17Univ Wuerzburg J MaximiliansTerapia in combinazione usando inibitori del fattore della crescita e della differenziazione 15 (gdf-15) umano e bloccanti del punto di controllo immunitario
WO2017055612A1 (en)*2015-10-022017-04-06Julius-Maximilians-Universität WürzburgGdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
US11213598B2 (en)*2015-11-122022-01-04The Board Of Trustees Of The Leland Stanford Junior UniversityLabeled probe and methods of use
BR112018010410A8 (pt)*2015-11-232019-02-26Five Prime Therapeutics Incmétodo para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
CN116063542A (zh)2015-12-022023-05-05阿吉纳斯公司抗体和其使用方法
GB201521391D0 (en)2015-12-032016-01-20Ucb Biopharma SprlAntibodies
GB201521393D0 (en)2015-12-032016-01-20Ucb Biopharma SprlAntibodies
GB201521383D0 (en)2015-12-032016-01-20Ucb Biopharma Sprl And Ucb CelltechMethod
GB201521389D0 (en)2015-12-032016-01-20Ucb Biopharma SprlMethod
GB201521382D0 (en)2015-12-032016-01-20Ucb Biopharma SprlAntibodies
KR20250057128A (ko)2015-12-302025-04-28코디악 사이언시스 인코포레이티드항체 및 이의 접합체
US11059885B2 (en)2016-05-132021-07-13Askgene Pharma Inc.Angiopoietin 2, VEGF dual antagonists
WO2017197199A1 (en)*2016-05-132017-11-16Askgene Pharma Inc.Novel angiopoietin 2, vegf dual antagonists
KR102356542B1 (ko)2016-05-202022-01-28리제너론 파마슈티칼스 인코포레이티드다중 가이드 RNAs를 이용한 면역학적 내성 파괴 방법
CN107459578B (zh)*2016-05-312021-11-26泰州迈博太科药业有限公司一种靶向cd47与pd-l1的双功能融合蛋白
MY200602A (en)2016-07-142024-01-04Bristol Myers Squibb CoAntibodies against tim3 and uses thereof
WO2018055023A1 (en)2016-09-222018-03-29INSERM (Institut National de la Santé et de la Recherche Médicale)Methods and pharmaceutical compositions for the treatment of lung cancer
IL265236B2 (en)*2016-09-292023-11-01Aebi Ltd Multipurpose medical buildings and their uses
BR112019006504A2 (pt)2016-10-062019-06-25Merck Patent Gmbhregime de dosagem de avelumabe para o tratamento de câncer
SG11201907299XA (en)2017-02-082019-09-27Dragonfly Therapeutics IncMulti-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
AU2018220736B2 (en)*2017-02-202024-10-24Dragonfly Therapeutics, Inc.Proteins binding HER2, NKG2D and CD16
EP3596122A1 (en)*2017-02-282020-01-22Bristol-Myers Squibb CompanyUse of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
CN106831995A (zh)*2017-03-312017-06-13北京百特美博生物科技有限公司新型双特异性抗体及其用途
EP3615075A4 (en)2017-04-242021-01-20Ohio State Innovation Foundation RECOMBINANT EGFL7, ANTI-EGFL7 ANTIBODIES, AND THEIR USES
KR20250010107A (ko)*2017-05-162025-01-20파이브 프라임 테라퓨틱스, 인크.암 치료에서 화학요법제와 병용되는 항-fgfr2 항체
WO2018217799A1 (en)*2017-05-232018-11-29Dragonfly Therapeutics, Inc.A protein binding nkg2d, cd16 and ror1 or ror2
EP3630836A1 (en)*2017-05-312020-04-08Elstar Therapeutics, Inc.Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
SG11202007579TA (en)2018-02-082020-09-29Dragonfly Therapeutics IncCombination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
JP7690286B2 (ja)2018-02-082025-06-10ドラゴンフライ セラピューティクス, インコーポレイテッドNkg2d受容体を標的とする抗体可変ドメイン
US12215157B2 (en)2018-02-202025-02-04Dragonfly Therapeutics, Inc.Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
JP2021514656A (ja)*2018-03-022021-06-17コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc.Il−6抗体ならびにその融合構築物およびコンジュゲート
EP3773724A2 (en)2018-04-122021-02-17UMC Utrecht Holding B.V.Drug combinations for use in the treatment of ras-mutant cancer
CA3100349A1 (en)*2018-05-172019-11-21The Board Of Trustees Of The Leland Stanford Junior UniversityReceptor inhibition by phosphatase recruitment
MA53284A (fr)2018-08-082022-01-26Dragonfly Therapeutics IncProtéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
CA3108427A1 (en)2018-08-082020-02-13Dragonfly Therapeutics, Inc.Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EA202091888A1 (ru)2018-08-082020-10-23Драгонфлай Терапьютикс, Инк.Вариабельные домены антител, нацеленные на рецептор nkg2d
TW202102539A (zh)*2019-04-012021-01-16美商伊梅塔斯科學療法公司結合蛋白、其製備方法、其組合物、其用途、編碼其之核酸分子及包含核酸分子之宿主細胞
BR112021023048A2 (pt)2019-05-212022-04-19Novartis AgMoléculas de ligação a cd19 e usos das mesmas
WO2021026024A1 (en)*2019-08-022021-02-11The Regents Of The University Of CaliforniaCompositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers
AU2020364071A1 (en)2019-10-102022-05-26Kodiak Sciences Inc.Methods of treating an eye disorder
TW202208428A (zh)2020-05-062022-03-01美商蜻蜓醫療公司結合nkg2d、cd16及clec12a之蛋白質
EP4149526A4 (en)*2020-05-142024-08-07Virtuoso Binco, Inc. HUMANIZED CD38 AND ICAM1 ANTIBODIES AND USES THEREOF
MX2023001490A (es)2020-08-052023-04-27Synthekine IncMoleculas de union a il27r\03b1 y metodos de uso.
WO2022031884A2 (en)2020-08-052022-02-10Synthekine, Inc.Il2rg binding molecules and methods of use
US12291572B2 (en)2020-08-052025-05-06Synthekine, Inc.IL12 receptor synthetic cytokines and methods of use
US11859001B2 (en)2020-08-052024-01-02Synthekine, Inc.IL12RB1-Binding molecules and methods of use
KR20230061390A (ko)2020-08-052023-05-08신테카인, 인크.Il27 수용체 결합과 관련된 조성물 및 방법
CA3190430A1 (en)2020-08-052022-02-10Synthekine, Inc.Il10rb binding molecules and methods of use
US12012457B1 (en)2020-08-052024-06-18Synthekine, Inc.IL23R binding molecules and methods of use
EP4192880A4 (en)2020-08-052025-04-30Synthekine, Inc. IL10 receptor-binding molecules and methods of use
US12018085B2 (en)2020-08-052024-06-25Synthekine, Inc.Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
WO2022032025A1 (en)*2020-08-052022-02-10Synthekine, Inc.Ifngr binding synthetic cytokines and methods of use
US12234291B2 (en)2020-08-052025-02-25Synthekine, Inc.IL2RB binding molecules and methods of use
US12122839B2 (en)2020-08-052024-10-22Synthekine, Inc.IFNGR binding synthetic cytokines and methods of use
US12297281B2 (en)2020-08-052025-05-13Synthekine, Inc.IL10RA binding molecules and methods of use
AU2021339962A1 (en)2020-09-142023-05-25Janssen Pharmaceutica NvFgfr inhibitor combination therapies
EP4301774A4 (en)2021-03-032025-08-13Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2023102875A1 (en)*2021-12-102023-06-15Multitude Therapeutics Inc.Anti-cdh6 antibody drug conjugate
CN116724057A (zh)*2022-11-282023-09-08浙江时迈药业有限公司蛋白酶可切割的重组双特异性抗体和组合物及其用途
WO2024137353A1 (en)*2022-12-222024-06-27Prometheus Biosciences, Inc.Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors
WO2024207070A1 (en)*2023-04-042024-10-10Telix Pharmaceuticals (Innovations) Pty LtdMethods of treating cancers expressing pdgfralpha
WO2024207047A1 (en)*2023-04-042024-10-10Telix Pharmaceuticals (Innovations) Pty LtdMethods of treating cancers expressing pdgfralpha
WO2024207069A1 (en)*2023-04-042024-10-10Telix Pharmaceuticals (Innovations) Pty LtdReagents and methods for imaging cancers expressing pdgfralpha
WO2024207046A1 (en)*2023-04-042024-10-10Telix Pharmaceuticals (Innovations) Pty LtdReagents and methods for imaging cancers expressing pdgfralpha
US20240358850A1 (en)*2023-04-132024-10-31MaineHealthCompositions and methods for an antibody drug conjugate directed to a non-cell surface therapeutic target
WO2025021790A2 (en)*2023-07-242025-01-30F. Hoffmann-La Roche AgMultispecific antibodies

Family Cites Families (316)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CU22545A1 (es)1994-11-181999-03-31Centro Inmunologia MolecularObtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
FR2413974A1 (fr)1978-01-061979-08-03David BernardSechoir pour feuilles imprimees par serigraphie
WO1981001145A1 (en)1979-10-181981-04-30Univ IllinoisHydrolytic enzyme-activatible pro-drugs
US4714681A (en)1981-07-011987-12-22The Board Of Reagents, The University Of Texas System Cancer CenterQuadroma cells and trioma cells and methods for the production of same
US4474893A (en)1981-07-011984-10-02The University of Texas System Cancer CenterRecombinant monoclonal antibodies
US4522811A (en)1982-07-081985-06-11Syntex (U.S.A.) Inc.Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en)1983-04-081989-03-28Genentech, Inc.Recombinant immunoglobin preparations
US4599304A (en)*1983-10-071986-07-08Becton, Dickinson And CompanyMethod for monitoring activated cell subpopulations
US6054561A (en)1984-02-082000-04-25Chiron CorporationAntigen-binding sites of antibody molecules specific for cancer antigens
JPS6147500A (ja)1984-08-151986-03-07Res Dev Corp Of Japanキメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en)1984-08-271987-11-25The Board Of Trustees Of The Leland Stanford Junior UniversityChimeric receptors by dna splicing and expression
GB8422238D0 (en)1984-09-031984-10-10Neuberger M SChimeric proteins
CA1319120C (en)1985-04-011993-06-15John Henry KentenTransformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5374548A (en)1986-05-021994-12-20Genentech, Inc.Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es)1985-06-261992-08-01Liposome Co IncMetodo para acoplamiento de liposomas.
US4676980A (en)1985-09-231987-06-30The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesTarget specific cross-linked heteroantibodies
EP0247091B1 (en)1985-11-011993-09-29Xoma CorporationModular assembly of antibody genes, antibodies prepared thereby and use
US5618920A (en)1985-11-011997-04-08Xoma CorporationModular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en)1986-01-231986-02-26Wilson R HNucleotide sequences
US5225539A (en)1986-03-271993-07-06Medical Research CouncilRecombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en)1987-01-081988-06-30Int Genetic EngPolynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en)1987-03-091987-04-15Carlton Med ProdDrug delivery systems
EP0307434B2 (en)1987-03-181998-07-29Scotgen Biopharmaceuticals, Inc.Altered antibodies
GB8717430D0 (en)1987-07-231987-08-26Celltech LtdRecombinant dna product
US4975278A (en)1988-02-261990-12-04Bristol-Myers CompanyAntibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5677425A (en)1987-09-041997-10-14Celltech Therapeutics LimitedRecombinant antibody
US5053394A (en)1988-09-211991-10-01American Cyanamid CompanyTargeted forms of methyltrithio antitumor agents
US5770701A (en)1987-10-301998-06-23American Cyanamid CompanyProcess for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en)1987-10-301997-02-25American Cyanamid CompanyAntitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5720937A (en)1988-01-121998-02-24Genentech, Inc.In vivo tumor detection assay
WO1989006692A1 (en)1988-01-121989-07-27Genentech, Inc.Method of treating tumor cells by inhibiting growth factor receptor function
US4925648A (en)1988-07-291990-05-15Immunomedics, Inc.Detection and treatment of infectious and inflammatory lesions
US5601819A (en)1988-08-111997-02-11The General Hospital CorporationBispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en)1988-09-021993-06-29Protein Engineering Corp.Directed evolution of novel binding proteins
GB8823869D0 (en)1988-10-121988-11-16Medical Res CouncilProduction of antibodies
FI903489A7 (fi)1988-11-111990-07-10Medical Res CouncilYhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
CA2006408A1 (en)*1988-12-271990-06-27Susumu IwasaBispecific monoclonal antibody, its production and use
US5530101A (en)1988-12-281996-06-25Protein Design Labs, Inc.Humanized immunoglobulins
ATE144793T1 (de)1989-06-291996-11-15Medarex IncBispezifische reagenzien für die aids-therapie
US5413923A (en)1989-07-251995-05-09Cell Genesys, Inc.Homologous recombination for universal donor cells and chimeric mammalian hosts
CA2026147C (en)1989-10-252006-02-07Ravi J. ChariCytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en)1989-10-251993-05-04Immunogen Inc.Cytotoxic agents comprising maytansinoids and their therapeutic use
US5196193A (en)1989-10-311993-03-23Ophidian Pharmaceuticals, Inc.Antivenoms and methods for making antivenoms
DK0463151T3 (da)1990-01-121996-07-01Cell Genesys IncFrembringelse af xenogene antistoffer
US5723286A (en)1990-06-201998-03-03Affymax Technologies N.V.Peptide library and screening systems
US6172197B1 (en)1991-07-102001-01-09Medical Research CouncilMethods for producing members of specific binding pairs
GB9015198D0 (en)1990-07-101990-08-29Brien Caroline J OBinding substance
US5625126A (en)1990-08-291997-04-29Genpharm International, Inc.Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)1990-08-291997-08-26Genpharm International Inc.Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)1990-08-291997-05-27Genpharm International, Inc.Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en)1990-08-291998-09-29Genpharm International Inc.Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko)1990-08-292000-11-15젠팜인터내셔날,인코포레이티드이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en)1990-08-291996-08-13Genpharm International, Inc.Ransgenic non-human animals for producing heterologous antibodies
CA2093022C (en)1990-10-052005-02-22Michael W. FangerTargeted immunostimulation with bispecific reagents
EP0557300B1 (en)1990-10-291997-11-19Chiron CorporationBispecific antibodies, method of production, and uses thereof
ES2113940T3 (es)1990-12-031998-05-16Genentech IncMetodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
WO1992015683A1 (en)1991-03-061992-09-17MERCK Patent Gesellschaft mit beschränkter HaftungHumanized and chimeric monoclonal antibodies
ES2093778T3 (es)1991-04-261997-01-01Surface Active LtdNuevos anticuerpos y metodos para su uso.
JPH06507398A (ja)1991-05-141994-08-25リプリジェン コーポレーションHiv感染治療のための異種複合抗体
US6407213B1 (en)1991-06-142002-06-18Genentech, Inc.Method for making humanized antibodies
US6800738B1 (en)1991-06-142004-10-05Genentech, Inc.Method for making humanized antibodies
US5637481A (en)1993-02-011997-06-10Bristol-Myers Squibb CompanyExpression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5270170A (en)1991-10-161993-12-14Affymax Technologies N.V.Peptide library and screening method
US5733731A (en)1991-10-161998-03-31Affymax Technologies N.V.Peptide library and screening method
US6027725A (en)1991-11-252000-02-22Enzon, Inc.Multivalent antigen-binding proteins
ES2227512T3 (es)1991-12-022005-04-01Medical Research CouncilProduccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5877289A (en)1992-03-051999-03-02The Scripps Research InstituteTissue factor compositions and ligands for the specific coagulation of vasculature
US5965132A (en)1992-03-051999-10-12Board Of Regents, The University Of Texas SystemMethods and compositions for targeting the vasculature of solid tumors
ATE239506T1 (de)1992-03-052003-05-15Univ TexasVerwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
EP0574048B1 (en)1992-03-132002-08-14Organon Teknika B.V.Peptides and nucleic acid sequences related to Epstein Barr Virus
ZA932522B (en)1992-04-101993-12-20Res Dev FoundationImmunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0640094A1 (en)1992-04-241995-03-01The Board Of Regents, The University Of Texas SystemRecombinant production of immunoglobulin-like domains in prokaryotic cells
JPH06105020B2 (ja)1992-06-091994-12-21ホッペ・アーゲーラッチ及びロックアップシステム
US5681714A (en)1992-07-301997-10-28Mount Sinai Hospital CorporationNucleic acid encoding tek receptor tyrosine kinase
CA2140280A1 (en)1992-08-171994-03-03Avi J. AshkenaziBispecific immunoadhesins
WO1994007921A1 (en)1992-09-251994-04-14Commonwealth Scientific And Industrial Research OrganisationTarget binding polypeptide
US5635483A (en)1992-12-031997-06-03Arizona Board Of Regents Acting On Behalf Of Arizona State UniversityTumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en)1993-01-261998-07-14Arizona Board Of RegentsElucidation and synthesis of selected pentapeptides
WO1994018221A1 (en)1993-02-021994-08-18The Scripps Research InstituteMethods for producing polypeptide binding sites
US6733752B1 (en)1994-03-302004-05-11The Trustees Of The University Of PennsylvaniaPrevention of tumors with monoclonal antibodies against neu
US5885573A (en)1993-06-011999-03-23Arch Development CorporationMethods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
JPH08511420A (ja)1993-06-161996-12-03セルテック・セラピューテイクス・リミテッド抗 体
US5922545A (en)1993-10-291999-07-13Affymax Technologies N.V.In vitro peptide and antibody display libraries
SE9400088D0 (sv)1994-01-141994-01-14Kabi Pharmacia AbBacterial receptor structures
US5643755A (en)1994-10-071997-07-01Regeneron Pharmaceuticals Inc.Nucleic acid encoding tie-2 ligand
US5879672A (en)1994-10-071999-03-09Regeneron Pharmaceuticals, Inc.Tie-2 ligand 1
GB9401182D0 (en)1994-01-211994-03-16Inst Of Cancer The ResearchAntibodies to EGF receptor and their antitumour effect
AUPM379494A0 (en)1994-02-101994-03-03Ludwig Institute For Cancer ResearchImmunointeractive molecules - ii
US5837458A (en)1994-02-171998-11-17Maxygen, Inc.Methods and compositions for cellular and metabolic engineering
US5834252A (en)1995-04-181998-11-10Glaxo Group LimitedEnd-complementary polymerase reaction
US5605793A (en)1994-02-171997-02-25Affymax Technologies N.V.Methods for in vitro recombination
AU692239B2 (en)1994-03-071998-06-04Medarex, Inc.Bispecific molecules having clinical utilities
US5733757A (en)1995-12-151998-03-31The Scripps Research InstituteAldolase catalytic antibody
US5773001A (en)1994-06-031998-06-30American Cyanamid CompanyConjugates of methyltrithio antitumor agents and intermediates for their synthesis
EP0771208B1 (en)1994-08-122005-10-19Immunomedics, Inc.Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5962216A (en)1994-08-191999-10-05La Region WallonneTumor-activated prodrug compounds and treatment
US5814464A (en)1994-10-071998-09-29Regeneron PharmaNucleic acids encoding TIE-2 ligand-2
US5650490A (en)1994-10-071997-07-22Regeneron Pharmaceuticals, Inc.Tie-2 ligand 2
US7063840B2 (en)1994-10-072006-06-20Regeneron Pharmaceuticals, Inc.TIE-2 ligands, methods of making and uses thereof
US5663149A (en)1994-12-131997-09-02Arizona Board Of Regents Acting On Behalf Of Arizona State UniversityHuman cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5731168A (en)1995-03-011998-03-24Genentech, Inc.Method for making heteromultimeric polypeptides
DE69633121T2 (de)1995-04-062005-07-28Regeneron Pharmaceuticals, Inc.Tie-2 liganden, herstellungsverfahren und verwendung
US6121022A (en)1995-04-142000-09-19Genentech, Inc.Altered polypeptides with increased half-life
US5869046A (en)1995-04-141999-02-09Genentech, Inc.Altered polypeptides with increased half-life
ATE390933T1 (de)1995-04-272008-04-15Amgen Fremont IncAus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en)1995-04-281996-10-31Abgenix, Inc.Human antibodies derived from immunized xenomice
US5712374A (en)1995-06-071998-01-27American Cyanamid CompanyMethod for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en)1995-06-071998-02-03American Cyanamid CompanyMethods for the preparation of monomeric calicheamicin derivative/carrier conjugates
EP0831880A4 (en)1995-06-072004-12-01Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
EP0873363B1 (en)1995-06-142010-10-06The Regents of The University of CaliforniaHigh affinity human antibodies to tumor antigens
DK2275119T3 (da)1995-07-272013-11-11Genentech IncStabil, isotonisk lyofiliseret proteinformulering
US6267958B1 (en)1995-07-272001-07-31Genentech, Inc.Protein formulation
US7264963B1 (en)1995-08-182007-09-04Morphosys AgProtein(poly)peptide libraries
JP4436457B2 (ja)1995-08-182010-03-24モルフォシス アイピー ゲーエムベーハー蛋白質/(ポリ)ペプチドライブラリー
AU7378096A (en)1995-09-281997-04-17Alexion Pharmaceuticals, Inc.Porcine cell interaction proteins
US5783186A (en)1995-12-051998-07-21Amgen Inc.Antibody-induced apoptosis
CN103275221B (zh)1996-02-092016-08-17艾伯维生物技术有限公司结合人TNFα的人抗体
US6194177B1 (en)1996-02-202001-02-27Applied Research Systems Ars Holding N.V.DNA encoding a hybrid heterodimeric protein
US20030040463A1 (en)1996-04-052003-02-27Wiegand Stanley J.TIE-2 ligands, methods of making and uses thereof
US7063965B2 (en)1996-04-052006-06-20Regeneron Pharmaceuticals, Inc.Nucleic acid encoding TIE-2 ligand
US6265564B1 (en)1996-08-022001-07-24Regeneron Pharmaceuticals, Inc.Expressed ligand-vascular intercellular signalling molecule
JP2001512560A (ja)1996-10-082001-08-21ユー―ビスイス ベスローテン フェンノートシャップ標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段
US5916771A (en)1996-10-111999-06-29Abgenix, Inc.Production of a multimeric protein by cell fusion method
WO1998018914A1 (en)1996-10-311998-05-07Duke UniversitySoluble tie2 receptor
KR100643058B1 (ko)1996-12-032006-11-13아브게닉스, 인크.복수의 Vн 및 Vк 영역을 함유하는 인간 면역글로불린 유전자좌를 갖는 트랜스제닉 포유동물 및 이로부터 생성된 항체
WO1998033914A1 (en)1997-01-311998-08-06University Of RochesterChimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US6277375B1 (en)1997-03-032001-08-21Board Of Regents, The University Of Texas SystemImmunoglobulin-like domains with increased half-lives
US6884879B1 (en)1997-04-072005-04-26Genentech, Inc.Anti-VEGF antibodies
DK0979281T3 (da)1997-05-022005-11-21Genentech IncFremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US20030207346A1 (en)1997-05-022003-11-06William R. ArathoonMethod for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en)1997-05-022002-05-23Genentech, Inc.Method for making multispecific antibodies having heteromultimeric and common components
US6235883B1 (en)1997-05-052001-05-22Abgenix, Inc.Human monoclonal antibodies to epidermal growth factor receptor
ATE319745T1 (de)1997-05-212006-03-15Biovation LtdVerfahren zur herstellung von nicht-immunogenen proteinen
US6207805B1 (en)1997-07-182001-03-27University Of Iowa Research FoundationProstate cell surface antigen-specific antibodies
AU8619698A (en)1997-07-251999-02-16Ban C. H. TsuiDevices, systems and methods for determining proper placement of epidural catheters
US6417168B1 (en)1998-03-042002-07-09The Trustees Of The University Of PennsylvaniaCompositions and methods of treating tumors
US6194551B1 (en)1998-04-022001-02-27Genentech, Inc.Polypeptide variants
US6528624B1 (en)1998-04-022003-03-04Genentech, Inc.Polypeptide variants
ID27512A (id)1998-04-212001-04-12Microment Ges Fur BiomedizinisPolipeptid tetapan cd19xcd3 dan kegunaan-kegunaannya
CN1305896C (zh)1998-05-062007-03-21基因技术股份有限公司用离子交换层析纯化蛋白质
GB9809951D0 (en)1998-05-081998-07-08Univ Cambridge TechBinding molecules
US6818213B1 (en)*1998-07-132004-11-16Board Of Regents, The University Of Texas SystemCancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6875741B2 (en)1998-09-022005-04-05Renuka PillutlaInsulin and IGF-1 receptor agonists and antagonists
EP1113810B1 (en)1998-09-142008-12-31Board of Regents, The University of Texas SystemMethods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding
US6365154B1 (en)1998-09-282002-04-02Smithkline Beecham CorporationTie2 agonist antibodies
US6376653B1 (en)1998-09-282002-04-23Smithkline Beecham PlcTie2 antagonist antibodies
US6660843B1 (en)1998-10-232003-12-09Amgen Inc.Modified peptides as therapeutic agents
AU776910B2 (en)1998-12-082004-09-23Merck Patent Gesellschaft Mit Beschrankter HaftungModifying protein immunogenicity
WO2000034337A1 (en)1998-12-102000-06-15Tsukuba Research Laboratory, Toagosei Co., Ltd.Humanized monoclonal antibodies against vascular endothelial cell growth factor
US7425541B2 (en)1998-12-112008-09-16Medarex, Inc.Enzyme-cleavable prodrug compounds
AU776393B2 (en)1998-12-232004-09-09Regeneron Pharmaceuticals, Inc.Method of enhancing the biological activity of ligands
US6737056B1 (en)1999-01-152004-05-18Genentech, Inc.Polypeptide variants with altered effector function
HUP0104865A3 (en)1999-01-152004-07-28Genentech IncPolypeptide variants with altered effector function
US6897044B1 (en)1999-01-282005-05-24Biogen Idec, Inc.Production of tetravalent antibodies
ES2313883T3 (es)1999-02-122009-03-16The Scripps Research InstituteProcedimientos para el tratamiento de tumores y metastasis utilizando una combinacion de terapias antiangiogenicas e inmunoterapias.
US6914128B1 (en)1999-03-252005-07-05Abbott Gmbh & Co. KgHuman antibodies that bind human IL-12 and methods for producing
US6455035B1 (en)1999-03-262002-09-24Regeneron Pharmaceuticals, Inc.Angiopoietins and methods of use thereof
EP1046715A1 (en)1999-04-232000-10-25Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
US7527787B2 (en)2005-10-192009-05-05Ibc Pharmaceuticals, Inc.Multivalent immunoglobulin-based bioactive assemblies
US6268488B1 (en)1999-05-252001-07-31Barbas, Iii Carlos F.Prodrug activation using catalytic antibodies
US6787637B1 (en)1999-05-282004-09-07Neuralab LimitedN-Terminal amyloid-β antibodies
US6521424B2 (en)1999-06-072003-02-18Immunex CorporationRecombinant expression of Tek antagonists
PT1187918E (pt)1999-06-072006-08-31Immunex CorpAntagonistas de tek
IL147017A0 (en)1999-06-252002-08-14Genentech IncTREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
US6949245B1 (en)1999-06-252005-09-27Genentech, Inc.Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
BRPI0012198B8 (pt)1999-06-252021-05-25Genentech Incanticorpos humanizados, composição e imunoconjugado
WO2001002588A2 (en)1999-07-022001-01-11Morphosys AgGeneration of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
DE60042693D1 (de)1999-08-272009-09-17Genentech IncDosierung für die behandlung mit anti erbb2-antikörpern
US6497909B1 (en)1999-09-092002-12-24General Mills, Inc.Method of bleaching cereal grain
US20030166858A1 (en)1999-09-162003-09-04Samuel DavisTIE-2 ligands, methods of making and uses thereof
US20050287153A1 (en)2002-06-282005-12-29Genentech, Inc.Serum albumin binding peptides for tumor targeting
US20040001827A1 (en)2002-06-282004-01-01Dennis Mark S.Serum albumin binding peptides for tumor targeting
DE60122286T2 (de)2000-02-112007-08-02Merck Patent GmbhSteigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US20040191260A1 (en)2003-03-262004-09-30Technion Research & Development Foundation Ltd.Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
KR20020093029A (ko)2000-04-112002-12-12제넨테크, 인크.다가 항체 및 그의 용도
AU2001257174A1 (en)2000-04-212001-11-07Amgen Inc.Integrin/adhesion antagonists
KR20130056201A (ko)2000-05-192013-05-29제넨테크, 인크.ErbB 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
US6725230B2 (en)2000-07-182004-04-20Aegis Analytical CorporationSystem, method and computer program for assembling process data of multi-database origins using a hierarchical display
ATE479761T1 (de)2000-07-312010-09-15Biolex Therapeutics IncExpression biologisch aktiver polypeptide in wasserlinse
US6596541B2 (en)2000-10-312003-07-22Regeneron Pharmaceuticals, Inc.Methods of modifying eukaryotic cells
US7105348B2 (en)2000-10-312006-09-12Regeneron Pharmaceuticals, Inc.Methods of modifying eukaryotic cells
ES2727425T3 (es)2000-12-122019-10-16Medimmune LlcMoléculas con semividas prolongadas, composiciones y usos de las mismas
US20040052785A1 (en)2001-01-092004-03-18Simon GoodmanCombination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
CN101684158A (zh)2001-01-172010-03-31特鲁比昂药品公司结合域-免疫球蛋白融合蛋白
US20030133939A1 (en)2001-01-172003-07-17Genecraft, Inc.Binding domain-immunoglobulin fusion proteins
US7754208B2 (en)2001-01-172010-07-13Trubion Pharmaceuticals, Inc.Binding domain-immunoglobulin fusion proteins
AU2002327164A1 (en)2001-01-292002-12-09Idec Pharmaceuticals CorporationEngineered tetravalent antibodies and methods of use
KR20040074587A (ko)2001-02-192004-08-25메르크 파텐트 게엠베하감소된 면역원성을 갖는 인공 단백질
JP4234438B2 (ja)2001-03-072009-03-04メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトングハイブリッド・イソタイプ抗体部分を含有する蛋白質の発現技術
US6441163B1 (en)2001-05-312002-08-27Immunogen, Inc.Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
IL145035A0 (en)2001-08-212002-06-30Yeda Res & DevMolecular linkers suitable for crystallization and structural analysis of molecules of interest and method of using same
US7138370B2 (en)2001-10-112006-11-21Amgen Inc.Specific binding agents of human angiopoietin-2
US7658924B2 (en)2001-10-112010-02-09Amgen Inc.Angiopoietin-2 specific binding agents
US7205275B2 (en)2001-10-112007-04-17Amgen Inc.Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en)2001-10-112009-04-21Amgen Inc.Angiopoietin-2 specific binding agents
EP2359685B1 (en)2001-12-272013-12-04GlycoFi, Inc.Methods to engineer mammalian-type carbohydrate structures
US20040002587A1 (en)2002-02-202004-01-01Watkins Jeffry D.Fc region variants
US20040132101A1 (en)2002-09-272004-07-08XencorOptimized Fc variants and methods for their generation
US7662925B2 (en)2002-03-012010-02-16Xencor, Inc.Optimized Fc variants and methods for their generation
EP1485492B1 (en)2002-03-192011-12-21Stichting Dienst Landbouwkundig OnderzoekGntiii (udp-n-acetylglucosamine:beta-d mannoside beta(1,4)-n-acetylglucosaminyltransferase iii) expression in plants
US7736652B2 (en)2002-03-212010-06-15The Regents Of The University Of CaliforniaAntibody fusion proteins: effective adjuvants of protein vaccination
US7332585B2 (en)2002-04-052008-02-19The Regents Of The California UniversityBispecific single chain Fv antibody molecules and methods of use thereof
US20070003514A1 (en)2002-04-052007-01-04The Regents Of The University Of CaliforniaMono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
ATE328906T1 (de)2002-06-282006-06-15Domantis LtdDual-specifische liganden mit erhöhter halbwertszeit
US20070104710A1 (en)2002-06-282007-05-10Domants LimitedLigand that has binding specificity for IL-4 and/or IL-13
BR0312534A (pt)2002-07-152007-03-13Genentech Incmétodo de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura
WO2006028429A2 (en)2002-08-052006-03-16The Johns Hopkins UniversityPeptides for targeting the prostate specific membrane antigen
ES2381617T5 (es)2002-08-142016-02-24Macrogenics, Inc.Anticuerpos específicos frente a FcgammaRIIB y sus procedimientos de uso
WO2004024927A1 (en)2002-09-122004-03-25Greenovation Biotech GmbhProtein production method
US20040057969A1 (en)2002-09-202004-03-25Smith Mark LCompositions containing stabilized hepatitis antigen and methods of their use
CN101987871A (zh)2002-09-272011-03-23赞科股份有限公司优化的Fc变体及其产生方法
US9809654B2 (en)2002-09-272017-11-07Vaccinex, Inc.Targeted CD1d molecules
US7541440B2 (en)2002-09-302009-06-02Immunomedics, Inc.Chimeric, human and humanized anti-granulocyte antibodies and methods of use
KR20050065587A (ko)2002-10-082005-06-29이뮤노메딕스, 인코오포레이티드항체 치료법
DK1549344T3 (da)2002-10-102015-04-07Merck Patent GmbhFarmaceutisk sammensætning rettet mod erb-b1 receptorer
ATE480562T1 (de)2002-10-152010-09-15Facet Biotech CorpVeränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
BRPI0316282B8 (pt)2002-11-152021-05-25Genmab Asanticorpo humano isolado monoclonal, composição, imunoconjugado, molécula biespecífica ou multiespecífica, método e conjunto de diagnóstico para detectar a presença de antígeno cd25 ou uma célula que expressa cd25, e, vetor de expressão
US7781197B2 (en)2002-12-202010-08-24Greenovation Biotech GmbhTransformed bryophyte cell having disrupted endogenous alpha 1,3-fucosyl and beta 1,2-xylosyl transferase encoding nucleotide sequences for the production of heterologous glycosylated proteins
JP2006524039A (ja)2003-01-092006-10-26マクロジェニクス,インコーポレーテッド変異型Fc領域を含む抗体の同定および作製ならびにその利用法
DE602004028337D1 (de)2003-01-222010-09-09Glycart Biotechnology AgFusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion
US7563869B2 (en)2003-01-232009-07-21Ono Pharmaceutical Co., Ltd.Substance specific to human PD-1
WO2004076650A2 (en)2003-02-272004-09-10The Trustees Of The University Of PennsylvaniaAngiopoietin and fragments, mutants, and analogs thereof and uses of the same
US6902962B2 (en)2003-04-042005-06-07Taiwan Semiconductor Manufacturing Company, Ltd.Silicon-on-insulator chip with multiple crystal orientations
US8088387B2 (en)2003-10-102012-01-03Immunogen Inc.Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
ATE455127T1 (de)2003-05-312010-01-15Micromet AgHumane anti-humane cd3-bindungsmoleküle
CA2534639C (en)2003-07-312013-07-30Immunomedics, Inc.Anti-cd19 antibodies
US7871610B2 (en)2003-08-122011-01-18Dyax Corp.Antibodies to Tie1 ectodomain
US7485297B2 (en)2003-08-122009-02-03Dyax Corp.Method of inhibition of vascular development using an antibody
GB0320878D0 (en)2003-09-052003-10-08Celltech R&D LtdA protein involved in carcinoma
GB0324368D0 (en)2003-10-172003-11-19Univ Cambridge TechPolypeptides including modified constant regions
EP3858387A1 (en)2003-11-062021-08-04Seagen Inc.Monomethylvaline compounds capable of conjugation to ligands
US7968684B2 (en)2003-11-122011-06-28Abbott LaboratoriesIL-18 binding proteins
US20050136044A1 (en)2003-12-042005-06-23Watkins Jeffry D.Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents
DK1709081T3 (da)2004-01-162011-06-06Regeneron PharmaFusionspolypeptider, der kan aktivere receptorer
WO2005089409A2 (en)2004-03-172005-09-29University Of HawaiiSensor constructs and detection methods
PT1735348E (pt)2004-03-192012-07-24Imclone LlcAnticorpo anti-receptor do factor de crescimento humano
US7976841B2 (en)2004-04-302011-07-12Institut National De La Sante Et De La RechercheAnti TfR antibody
CN1997382A (zh)2004-05-052007-07-11梅里麦克制药股份有限公司调节生物活性的双特异性结合剂
JP2008504248A (ja)2004-06-252008-02-14ライセンティア・リミテッドTie受容体およびTieリガンド物質および雌受胎能を制御する方法
WO2006005361A1 (en)2004-07-132006-01-19Centre National De La Recherche ScientifiquePeptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses
MX2007001345A (es)2004-08-042008-03-11Applied Molecular EvolutionRegiones variantes fc.
AU2005272848A1 (en)2004-08-122006-02-23Dyax Corp.Tie complex binding proteins
CA2577082A1 (en)2004-09-022006-03-16Genentech, Inc.Heteromultimeric molecules
WO2006034488A2 (en)2004-09-232006-03-30Genentech, Inc.Cysteine engineered antibodies and conjugates
CA2580796C (en)2004-09-242013-03-26Amgen Inc.Modified fc molecules having peptides inserted in internal loop regions
WO2007001457A2 (en)2004-11-122007-01-04Xencor, Inc.Antibodies operably linked to selected chemoattractants
EP1819731A4 (en)2004-12-082013-02-13Immunomedics Inc METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER
KR101017301B1 (ko)2004-12-212011-02-28메드임뮨 리미티드앤지오포이에틴-2에 대한 항체 및 그의 용도
KR20130105885A (ko)2005-01-052013-09-26에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하.상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을 갖는 합성 면역글로불린 영역
KR20150083139A (ko)2005-01-212015-07-16제넨테크, 인크.Her 항체의 고정 용량 투여법
US7700099B2 (en)2005-02-142010-04-20Merck & Co., Inc.Non-immunostimulatory antibody and compositions containing the same
KR20070114765A (ko)2005-02-232007-12-04메리맥 파마슈티컬즈, 인크.생물학적 활성을 조절하기 위한 이특이성 결합제
WO2006106905A1 (ja)2005-03-312006-10-12Chugai Seiyaku Kabushiki Kaisha会合制御によるポリペプチド製造方法
EP1896503B1 (en)2005-05-312014-10-29Board of Regents, The University of Texas SystemIgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF
CA2615122A1 (en)2005-08-032007-02-15Immunogen, Inc.Immunoconjugate formulations
US8008453B2 (en)2005-08-122011-08-30Amgen Inc.Modified Fc molecules
US7612181B2 (en)2005-08-192009-11-03Abbott LaboratoriesDual variable domain immunoglobulin and uses thereof
EP2495257A3 (en)2005-08-192012-10-17Abbott LaboratoriesDual variable domain immunoglobulin and uses thereof
US7438381B2 (en)2005-10-112008-10-21Silverbrook Research Pty LtdMethod of removing flooded ink from a printhead
WO2007097812A2 (en)2005-11-032007-08-30Genentech, Inc.Therapeutic anti-her2 antibody fusion polypeptides
CA2627190A1 (en)2005-11-102007-05-24Medarex, Inc.Duocarmycin derivatives as novel cytotoxic compounds and conjugates
EP1790358A1 (en)2005-11-232007-05-30Université de Reims Champagne-ArdennesProtein constructs designed for targeting and lysis of cells
GB0524788D0 (en)2005-12-052006-01-11Affibody AbPolypeptides
EP1963370A1 (en)2005-12-062008-09-03Domantis LimitedBispecific ligands with binding specificity to cell surface targets and methods of use therefor
EA013878B1 (ru)2005-12-062010-08-30Домантис ЛимитедЛиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
AU2006324477A1 (en)2005-12-152007-06-21Medimmune LimitedCombination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer
CN103242451B (zh)2005-12-162017-11-21Ibc医药公司基于免疫球蛋白的多价生物活性装配体
AR059066A1 (es)2006-01-272008-03-12Amgen IncCombinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CN106986941B (zh)2006-02-022021-12-31综合医院公司改造抗体-应激蛋白融合物
EP1820513A1 (en)2006-02-152007-08-22Trion Pharma GmbhDestruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
WO2007095746A1 (en)2006-02-242007-08-30Arius Research Inc.Cancerous disease modifying antibodies
AU2007225044C1 (en)2006-03-152018-03-29Alexion Pharmaceuticals, Inc.Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
SMP200800064B (it)2006-04-212009-11-06Novartis AgComposizioni farmaceutiche di anticorpi anti-cd40 antagonista
US20100021379A1 (en)2006-06-292010-01-28The Regents Of The University Of CaliforniaChemical Antibodies for Immunotherapy and Imaging
AT503889B1 (de)2006-07-052011-12-15Star Biotechnologische Forschungs Und Entwicklungsges M B H FMultivalente immunglobuline
BRPI0714728A2 (pt)2006-08-042013-05-14Astrazeneca Abagente de ligaÇço alvejado, anticorpo, composiÇço, linhagem de cÉlula isolada molÉcula de Ácido nucleico isolada, vetor, cÉlula hospedeira, mÉtodos para produzir um agente de ligaÇço alvejado, para isolar um anticorpo ou porÇço de ligaÇço de antÍgeno do mesmo, para fabricar um anticorpo monoclonal humano, para tratar, prevenir ou aliviar os sintomas de um distérbio, para inibir a proliferaÇço de uma cÉlula cancerosa, para inibir uma atividade de erbb2 em uma cÉlula que expressa erbb2, e para modular uma atividade de erbb2 em uma cÉlula que expressa erbb2, e, animal transgÊnico nço humano ou planta transgÊnica
US8497246B2 (en)*2006-08-182013-07-30Armagen Technologies, Inc.Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
EP2083017A4 (en)2006-09-142011-01-12Med & Biological Lab Co Ltd ANTIBODIES HAVING INCREASED ADCC ACTIVITY AND METHOD FOR PRODUCING THE SAME
UA98943C2 (ru)2006-10-022012-07-10Ридженерон Фармасьютикалз, Инк.Високоаффинные антитела человека к рецептору il-4 человека
DK2076290T3 (da)2006-10-272017-01-23Sunnybrook Health Sciences CenterMultimeriske tie 2-agonister og anvendelser deraf ved stimulering af angiogenese
WO2008070042A2 (en)2006-12-042008-06-12Medimmune, Inc.High potency recombinant antibodies, methods for producing them and use in cancer therapy
KR20140148491A (ko)2006-12-192014-12-31제넨테크, 인크.조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 vegf-특이적 길항제
JP2010516675A (ja)2007-01-172010-05-20イミューノメディクス、インコーポレイテッド治療薬剤のポリマー担体および疾病部位の抗体に基づく標的化のための認識部分
EP2684889A3 (en)2007-02-022014-03-05Baylor Research InstituteMultivariable antigens complexed with targeting humanized monoclonal antibody
US10259860B2 (en)2007-02-272019-04-16Aprogen Inc.Fusion proteins binding to VEGF and angiopoietin
NZ578824A (en)2007-03-022012-03-30Genentech IncPredicting response to a her dimerisation inhibitor based on low her3 expression
GB2447689B (en)2007-03-222011-08-24Knorr Bremse SystemeTrailer electronic braking system
EP2139524A1 (en)2007-03-232010-01-06The Governors of the University of AlbertaMultivalent heterobifunctional polymers and methods of their use
AU2008282218A1 (en)2007-07-312009-02-05Medimmune, LlcMultispecific epitope binding proteins and uses thereof
CA2705292C (en)2007-11-132016-06-21Teva Biopharmaceuticals Usa, Inc.Humanized antibodies against tl1a
CA2706419A1 (en)2007-11-302009-06-04Glaxo Group LimitedAntigen-binding constructs binding il-13
US20090162359A1 (en)*2007-12-212009-06-25Christian KleinBivalent, bispecific antibodies
US8454960B2 (en)2008-01-032013-06-04The Scripps Research InstituteMultispecific antibody targeting and multivalency through modular recognition domains
AU2008346734A1 (en)2008-01-032009-07-16The Scripps Research InstituteAntibody targeting through a modular recognition domain
US8557242B2 (en)2008-01-032013-10-15The Scripps Research InstituteERBB2 antibodies comprising modular recognition domains
US8574577B2 (en)2008-01-032013-11-05The Scripps Research InstituteVEGF antibodies comprising modular recognition domains
US20140127200A1 (en)2008-01-032014-05-08The Scripps Research InstituteMultispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
US8557243B2 (en)2008-01-032013-10-15The Scripps Research InstituteEFGR antibodies comprising modular recognition domains
US8507656B2 (en)2008-01-282013-08-13Medimmune LimitedStabilized angiopoietin-2 antibodies and uses thereof
JO2913B1 (en)2008-02-202015-09-15امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2113255A1 (en)2008-05-022009-11-04f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.Cytotoxic immunoglobulin
WO2009142460A2 (en)2008-05-232009-11-26Samsung Electronics Co., Ltd.Antibody-peptide fused synergibody
EP2671891A3 (en)2008-06-272014-03-05Amgen Inc.Ang-2 inhibition to treat multiple sclerosis
AU2009275135A1 (en)2008-07-212010-01-28Compugen Ltd.Angiopoietin derived peptides
US8268314B2 (en)2008-10-082012-09-18Hoffmann-La Roche Inc.Bispecific anti-VEGF/anti-ANG-2 antibodies
US8858940B2 (en)2008-12-102014-10-14Ablynx N.V.Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
US8133979B2 (en)2008-12-162012-03-13Hoffmann-La Roche Inc.Antibodies against human angiopoietin 2
PL2396036T3 (pl)2009-02-132017-12-29Immunomedics, Inc.Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
CA2755336C (en)2009-03-202015-07-14Amgen Inc.Carrier immunoglobulins and uses thereof
US8703132B2 (en)2009-06-182014-04-22Hoffmann-La Roche, Inc.Bispecific, tetravalent antigen binding proteins
JO3182B1 (ar)2009-07-292018-03-08Regeneron Pharmaمضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
KR101688522B1 (ko)2009-12-152016-12-21삼성전자주식회사안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
US20120100166A1 (en)2010-07-152012-04-26Zyngenia, Inc.Ang-2 Binding Complexes and Uses Thereof
CA2827170A1 (en)*2011-02-112012-08-16David M. HilbertMonovalent and multivalent multispecific complexes and uses thereof
ES2704038T3 (es)2011-05-242019-03-13Zyngenia IncComplejos multiespecíficos multivalentes y monovalentes y sus usos
CN105451767B (zh)2013-03-152019-10-18泽恩格尼亚股份有限公司多价和单价多特异性复合物及其用途

Also Published As

Publication numberPublication date
NZ719602A (en)2020-02-28
NZ618334A (en)2016-05-27
AU2017204032B2 (en)2019-10-03
CN103857699A (zh)2014-06-11
US20140065142A1 (en)2014-03-06
EP2714738B1 (en)2018-10-10
CN103857699B (zh)2016-08-31
WO2012162561A3 (en)2013-05-02
WO2012162561A2 (en)2012-11-29
AU2012258637A1 (en)2013-12-19
AU2017204032A1 (en)2017-07-06
ES2704038T3 (es)2019-03-13
AU2012258637B2 (en)2017-07-20
US10526381B2 (en)2020-01-07
US20150210765A1 (en)2015-07-30
CA2837169C (en)2021-11-09
CA2837169A1 (en)2012-11-29
CN106432506A (zh)2017-02-22
EP2714738A2 (en)2014-04-09
US20170298106A1 (en)2017-10-19

Similar Documents

PublicationPublication DateTitle
AU2017204032B2 (en)Multivalent and monovalent multispecific complexes and their uses
US10150800B2 (en)EGFR-binding modular recognition domains
US10087222B2 (en)Polynucleotides encoding angiopoietin-2 (ang-2) binding polypeptides
US20140088019A1 (en)Monovalent and Multivalent Multispecific Complexes and Uses Thereof
WO2014028776A1 (en)Monovalent and multivalent multispecific complexes and uses thereof
HK1234424A1 (en)Multivalent and monovalent multispecific complexes and their uses
NZ719602B2 (en)Multivalent and monovalent multispecific complexes and their uses
NZ618334B2 (en)Multivalent and monovalent multispecific complexes and their uses
HK1222981B (zh)多价和单价多特异性复合物及其用途
EA043040B1 (ru)Пептид, связывающий ангиопоэтин-2, мультиспецифические комплексы, содержащие указанный пептид и антитела, и их применение

[8]ページ先頭

©2009-2025 Movatter.jp